Ideas like NO donors, phosphodiesterase inhibitors, soluble guanylyl cyclase activators, and immunomodulators could shake up current treatments, maybe even help patients beat drug resistance or live longer, as some clinical studies backing this up, showing how NOS levels and NO activity shift in cancer tissues and track with how the disease progresses. This evidence concerns the gene NOS1 and cancer.